250 related articles for article (PubMed ID: 22317762)
1. Statistical issues and recommendations for noninferiority trials in oncology: a systematic review.
Tanaka S; Kinjo Y; Kataoka Y; Yoshimura K; Teramukai S
Clin Cancer Res; 2012 Apr; 18(7):1837-47. PubMed ID: 22317762
[TBL] [Abstract][Full Text] [Related]
2. Quality of reporting of noninferiority and equivalence randomized trials.
Le Henanff A; Giraudeau B; Baron G; Ravaud P
JAMA; 2006 Mar; 295(10):1147-51. PubMed ID: 16522835
[TBL] [Abstract][Full Text] [Related]
3. Systematic qualitative review of randomised trials conducted in nonsmall cell lung cancer with a noninferiority or equivalence design.
Paesmans M; Grigoriu B; Ocak S; Roelandts M; Lafitte JJ; Holbrechts S; Berghmans T; Meert AP; Moretti L; Danyi S; Pasleau F; Ameye L; Van Meerhaeghe A; Sculier JP
Eur Respir J; 2015 Feb; 45(2):511-24. PubMed ID: 25537559
[TBL] [Abstract][Full Text] [Related]
4. Comparison of noninferiority margins reported in protocols and publications showed incomplete and inconsistent reporting.
Dekkers OM; Cevallos M; Bührer J; Poncet A; Ackermann Rau S; Perneger TV; Egger M
J Clin Epidemiol; 2015 May; 68(5):510-7. PubMed ID: 25450451
[TBL] [Abstract][Full Text] [Related]
5. A systematic review of noninferiority margins in oncology clinical trials.
Hashim M; Vincken T; Kroi F; Gebregergish S; Spencer M; Wang J; Kampfenkel T; Lam A; He J
J Comp Eff Res; 2021 Apr; 10(6):443-455. PubMed ID: 33728935
[No Abstract] [Full Text] [Related]
6. Three-arm noninferiority trials with a prespecified margin for inference of the difference in the proportions of binary endpoints.
Hida E; Tango T
J Biopharm Stat; 2013; 23(4):774-89. PubMed ID: 23799810
[TBL] [Abstract][Full Text] [Related]
7. Mixed noninferiority margin and statistical tests in active controlled trials.
Tsou HH; Hsiao CF; Chow SC; Yue L; Xu Y; Lee S
J Biopharm Stat; 2007; 17(2):339-57. PubMed ID: 17365228
[TBL] [Abstract][Full Text] [Related]
8. Choice of delta noninferiority margin and dependency of the noninferiority trials.
Tsong Y; Zhang J; Levenson M
J Biopharm Stat; 2007; 17(2):279-88. PubMed ID: 17365224
[TBL] [Abstract][Full Text] [Related]
9. A literature review of applied adaptive design methodology within the field of oncology in randomised controlled trials and a proposed extension to the CONSORT guidelines.
Mistry P; Dunn JA; Marshall A
BMC Med Res Methodol; 2017 Jul; 17(1):108. PubMed ID: 28720094
[TBL] [Abstract][Full Text] [Related]
10. Methodological quality of oncology noninferiority clinical trials.
Wayant C; Ross A; Vassar M
Crit Rev Oncol Hematol; 2020 May; 149():102938. PubMed ID: 32172223
[TBL] [Abstract][Full Text] [Related]
11. Comparative effectiveness clinical trials in psychiatry: superiority, noninferiority, and the role of active comparators.
Leon AC
J Clin Psychiatry; 2011 Oct; 72(10):1344-9. PubMed ID: 21367350
[TBL] [Abstract][Full Text] [Related]
12. Deficiencies in health-related quality-of-life assessment and reporting: a systematic review of oncology randomized phase III trials published between 2012 and 2016.
Marandino L; La Salvia A; Sonetto C; De Luca E; Pignataro D; Zichi C; Di Stefano RF; Ghisoni E; Lombardi P; Mariniello A; Reale ML; Trevisi E; Leone G; Muratori L; Marcato M; Bironzo P; Novello S; Aglietta M; Scagliotti GV; Perrone F; Di Maio M
Ann Oncol; 2018 Dec; 29(12):2288-2295. PubMed ID: 30304498
[TBL] [Abstract][Full Text] [Related]
13. Empirical Consequences of Current Recommendations for the Design and Interpretation of Noninferiority Trials.
Aberegg SK; Hersh AM; Samore MH
J Gen Intern Med; 2018 Jan; 33(1):88-96. PubMed ID: 28875400
[TBL] [Abstract][Full Text] [Related]
14. Protocol adherence rates in superiority and noninferiority randomized clinical trials published in high impact medical journals.
Bamat NA; Ekhaguere OA; Zhang L; Flannery DD; Handley SC; Herrick HM; Ellenberg SS
Clin Trials; 2020 Oct; 17(5):552-559. PubMed ID: 32666826
[TBL] [Abstract][Full Text] [Related]
15. Assessing the Justification, Funding, Success, and Survival Outcomes of Randomized Noninferiority Trials of Cancer Drugs: A Systematic Review and Pooled Analysis.
Gyawali B; Tessema FA; Jung EH; Kesselheim AS
JAMA Netw Open; 2019 Aug; 2(8):e199570. PubMed ID: 31469391
[TBL] [Abstract][Full Text] [Related]
16. Ophthalmic randomized controlled trials reports: the statement of the hypothesis.
Lee CF; Cheng AC; Fong DY
Am J Ophthalmol; 2014 Jan; 157(1):254-259.e1. PubMed ID: 24210767
[TBL] [Abstract][Full Text] [Related]
17. Issues with statistical risks for testing methods in noninferiority trial without a placebo ARM.
Hung HM; Wang SJ; O'Neill R
J Biopharm Stat; 2007; 17(2):201-13. PubMed ID: 17365218
[TBL] [Abstract][Full Text] [Related]
18. Unresolved issues with noninferiority pragmatic trials: Results of a literature survey.
Ciarleglio MM; Li J; Peduzzi P
Clin Trials; 2024 Apr; 21(2):242-256. PubMed ID: 37927102
[TBL] [Abstract][Full Text] [Related]
19. Evaluating equivalence and noninferiority trials.
Dasgupta A; Lawson KA; Wilson JP
Am J Health Syst Pharm; 2010 Aug; 67(16):1337-43. PubMed ID: 20689122
[TBL] [Abstract][Full Text] [Related]
20. Noninferiority testing beyond simple two-sample comparison.
Tsong Y; Chen WJ
J Biopharm Stat; 2007; 17(2):289-308. PubMed ID: 17365225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
